TABLE III.
Exploratory Peri- and Postnatal Development Preclinical Study
| Rat pups (n) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dasatinib (mg/kg/day) | ||||||||||||
| 0 | 5 | 10 | ||||||||||
| Start of dasatinib treatment | Died | M | F | NE | Died | M | F | NE | Died | M | F | NE |
| Gestation day 16 | 2 (2%) | N/A | N/A | N/A | 23 (25%) | 25 | 22 | 45 | 57 (89%) | 4 | 1 | 59 |
| Pleural effusion | N/A | N/A | N/A | N/A | 18 | 13 | 7 | N/A | 0 | 0 | 0 | N/A |
| Gestation day 21 | 1 (2%) | N/A | N/A | N/A | 58 (57%) | 22 | 20 | 60 | 46 (60%) | 20 | 10 | 47 |
| Pleural effusion | N/A | N/A | N/A | N/A | 16 | 9 | 7 | N/A | 30 | 20 | 10 | N/A |
| Lactation day 4 | 0 | 40 | 28 | 33 | 0 | 29 | 42 | 32 | 33 (34%) | 31 | 26 | 40 |
| Pleural effusion | 0 | 0 | 0 | N/A | 0 | 0 | 0 | N/A | 25 | 10 | 15 | N/A |
F, viable female; M, viable male; N/A, not applicable; NE, not examined.